Related Experiment Videos

The safety of statins in children

Norman Lamaida1, Ernesto Capuano, Laura Pinto

  • 1Department of Cardiology, Mercato san Severino Hospital, Salerno, Italy. normanlamaida@libero.it

Acta Paediatrica (Oslo, Norway : 1992)
|May 2, 2013
PubMed

Insights

Statins are recommended for children aged 8 and up to manage high cholesterol. While short-term studies show statin monotherapy is safe and effective in kids, long-term safety data is still needed.

Area of Science:

  • Pediatrics
  • Cardiology
  • Pharmacology

Background:

  • Current guidelines suggest statins as a first-line treatment for children as young as 8 years old.
  • Hypercholesterolemia in children requires effective and safe management strategies.

Purpose of the Study:

  • To evaluate the safety of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in pediatric patients with hypercholesterolemia.

Main Methods:

  • Review of controlled studies assessing statin use in children.
  • Analysis of short-term efficacy, tolerability, and safety data.

Main Results:

  • Statin monotherapy demonstrated efficacy and good tolerability in children during short-term follow-up.
  • Short-term safety profiles were favorable in the studied pediatric population.

Conclusions:

  • Short-term controlled studies indicate that statin monotherapy is safe and effective for children.
  • Long-term safety data for statin use in pediatric hypercholesterolemia remains to be established due to limited follow-up periods.
Abstract

Keywords:
ChildrenHMG-CoA reductase inhibitorsSafety

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...